SG Americas Securities LLC Purchases 43,230 Shares of LeMaitre Vascular, Inc. $LMAT

SG Americas Securities LLC boosted its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 343.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,809 shares of the medical instruments supplier’s stock after acquiring an additional 43,230 shares during the quarter. SG Americas Securities LLC’s holdings in LeMaitre Vascular were worth $4,526,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Cornerstone Planning Group LLC boosted its stake in LeMaitre Vascular by 534.0% during the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 283 shares during the last quarter. MAI Capital Management purchased a new position in shares of LeMaitre Vascular in the third quarter worth $38,000. First Horizon Corp bought a new position in shares of LeMaitre Vascular during the third quarter valued at $39,000. Geneos Wealth Management Inc. lifted its holdings in shares of LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares in the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new stake in shares of LeMaitre Vascular during the second quarter valued at $47,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $108.75 on Thursday. The firm has a market capitalization of $2.48 billion, a P/E ratio of 43.33, a PEG ratio of 3.14 and a beta of 0.67. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $115.33. The business has a fifty day moving average of $98.21 and a 200 day moving average of $90.43.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The company had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.LeMaitre Vascular’s revenue was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were paid a $0.25 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date was Thursday, March 12th. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 39.84%.

Analyst Ratings Changes

LMAT has been the subject of a number of recent analyst reports. Weiss Ratings raised LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, March 10th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Citizens Jmp boosted their price objective on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Finally, Roth Mkm restated a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $105.80.

Insider Buying and Selling

In other LeMaitre Vascular news, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the sale, the insider directly owned 6,677 shares of the company’s stock, valued at approximately $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David B. Roberts sold 8,464 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the completion of the transaction, the director owned 17,979 shares in the company, valued at $1,920,157.20. The trade was a 32.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 215,438 shares of company stock valued at $23,062,911. 9.50% of the stock is owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.